Octanate
SUMMARY OF PRODUCT CHARACTERISTICS
1 Name of the Medicinal Product
Octanate 100 IU/ml
Powder and solvent for solution for injection
2 Qualitative and Quantitative Composition
Octanate
100 IU/mlcontains nominally 1000 IU human coagulation
factor VIII per vial.
The product contains approximately 100 IU* per ml human
coagulation factor VIII when reconstituted with 10 ml of
solvent.
Produced from the plasma of human donors.
The product contains approximately ≤ 60 IU per ml von Willebrand factor (VWF:RCo).
Excipient with known effect:
Sodium up to 1.75 mmol (40 mg) per dose
Sodium concentration after reconstitution: 125 – 175 mmol/l
For the full list of excipients, see section 6.1.
* The potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The mean specific activity of Octanate is ≥ 100 IU/mg protein.
3 Pharmaceutical Form
Powder and solvent for solution for injection.
The powder is white or pale yellow, also appearing as a friable solid.
The solvent is a clear, colourless liquid.
4 Clinical Particulars
4.1 Therapeutic indications
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency)
This preparation does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand’s disease.
4.2 Posology and method of administration
Treatment should be under the supervision of a physician experienced in the treatment of haemophilia.
Posology
The dose and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding, and on the patient’s clinical condition.
The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current World Health Organisation (WHO) international standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an International Standard for factor VIII in plasma).
On-demand treatment
One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma. The calculation of the required dosage of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 1.5 % to 2 % of normal activity. The required dosage is determined using the following formula:
Required units = body weight (kg) x desired factor VIII rise (%) (IU/dl) x 0.5
The amount and frequency of administration should always be adjusted according to the clinical effectiveness in the individual patient.
In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma activity level (in % of normal) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery:
|
Degree of
haemorrhage/ |
Factor VIII level |
Frequency of doses (hours) / Duration of therapy (days) |
|
Haemorrhage |
|
|
|
Early haemarthrosis, muscle bleeding or oral bleeding |
20 - 40 |
Repeat every 12 to 24 hours. At least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved. |
|
More extensive haemarthrosis, muscle bleeding or haematoma |
30 - 60 |
Repeat infusion every 12 to 24 hours for 3 to 4 days or more until pain and disability are resolved. |
|
Life-threatening haemorrhages |
60 - 100 |
Repeat infusion every 8 to 24 hours until threat is resolved. |
|
Surgery |
|
|
|
Minor |
30 - 60 |
Every 24 hours, at least 1 day, until healing is achieved. |
|
Major |
80 - 100 |
Repeat infusion every 8 to 24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a FVIII activity of 30% to 60%. |
Prophylaxis
For
long-term prophylaxis against bleeding in patients with severe
haemophilia A, the usual doses are 20 to 40 IU of factor VIII per
kg body weight at intervals of 2 to 3 days. In some cases,
especially in younger patients, shorter dosage intervals or higher
does may be necessary.
Continuous infusion
Prior to surgery, a pharmacokinetic analysis should be performed to obtain an estimate of clearance.
The initial infusion rate can be calculated as follows: Clearance x desired steady state level = infusion rate (IU/kg/hr).
After the initial 24 hours of continuous infusion, the clearance should be calculated again every day using the steady state equation with the measured level and the known rate of infusion.
During the course of treatment, appropriate
determination of factor VIII level is advised to guide the dose to
be administered and the frequency of repeated infusions. In the
case of major surgical interventions in particular, a precise
monitoring of the substitution therapy by means of coagulation
analysis (plasma factor VIII activity) is indispensable. Individual
patients may vary in their response to factor VIII, demonstrating
different half-lives and recoveries.
Previously untreated patients
Clinical
data on the use of Octanate in previously untreated patients (PUPs)
are limited. Currently available data are described in section
4.8.
Paediatric population
A
clinical study which was conducted in 15 patients of 6 years of age
or less did not identify any special dosage requirements for
children.
Method of administration
Intravenous use.
It is recommended not to administer more than 2–3 mL per minute.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Hypersensitivity
Allergic type hypersensitivity reactions are possible with Octanate. The product contains traces of human proteins other than factor VIII. If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.
In case of shock, standard medical treatment of shock should be implemented.
Inhibitors
The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication of the treatment of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay. The risk of developing inhibitors is correlated to the exposure to anti-haemophilic factor VIII, this risk being highest within the first 20 exposure days. Rarely, inhibitors may develop after the first 100 exposure days.
Cases of recurrent inhibitor (low titre) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a previous history of inhibitor development. Therefore, it is recommended to monitor all patients carefully for inhibitor occurrence following any product switch.
In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.
Catheter-related complications
If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered.
Transmissible agents
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and for the non-enveloped virus hepatitis A virus (HAV). The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (foetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. hemolytic anaemia).
Appropriate vaccination (hepatitis A and B) should be considered for patients in regular/repeated receipt of human plasma-derived factor VIII products.
It is strongly recommended that every time Octanate is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
This medicinal product contains up to 1.75 mmol sodium (40 mg) per dose. To be taken into consideration by patients on a controlled sodium diet.
Paediatric population
The listed warnings and precautions apply to both adults and children.
4.5 Interaction with other medicinal products and other forms of interaction
No interactions of human coagulation factor VIII products with other medicinal products have been reported.
4.6 Fertility, pregnancy and lactation
Animal reproduction studies have not been conducted with factor VIII. Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breast-feeding is not available. Therefore, factor VIII should be used during pregnancy and lactation only if clearly indicated.
4.7 Effects on ability to drive and use machines
Octanate has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effects
Summary of the safety profile
Hypersensitivity or allergic reactions (which may include angiooedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, chest tightness, tingling, vomiting, wheezing) have been observed rarely and may in some cases progress to severe anaphylaxis (including shock).
On rare occasions, fever has been observed.
Patients with haemophilia A may develop antibodies (inhibitors) to factor VIII. If such inhibitors occur, the condition will manifest as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.
For safety information with respect to transmissible agents, see section 4.4.
Tabulated list of adverse reactions
The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).
Frequencies have been evaluated according to the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
|
MedDRA Standard System Organ Class |
Rare |
Very rare |
|
Immune system disorders |
Hypersensitivity |
Anaphylactic shock |
|
General disorders and administration site conditions |
Pyrexia |
|
|
Investigations |
Anti factor VIII antibody positive |
|
Paediatric population
Frequency, type and severity of adverse reactions in children are the same as in adults.
Previously untreated patients
In an ongoing clinical trial in previously untreated patients (PUPs), 3 out of 39 (7.6%) PUPs treated with Octanate on-demand developed inhibitors with a titre above 5 BU. One patient developed inhibitors with a titre below 5 BU. Two cases (5.1%) were of clinical relevance; the remaining two subjects displayed inhibitors that disappeared spontaneously without an Octanate dose change. All inhibitors developed with on-demand treatment and before exposure day 50.
35 PUPs had a baseline FVIII activity 1% and 4 PUPs had 2% FVIII:C. At the time point of the interim analysis, there were 34 patients who had already 20 or more exposure days to Octanate and 30 patients with 50 or more exposure days to Octanate. No inhibitors were observed in PUPs receiving prophylaxis with Octanate. During the study, 12 PUPs underwent 14 surgical procedures. The median age at the first exposure was 7 months (range 3 days to 67 months). The median number of exposure days in the clinical trial was 100 (range 1-553).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medical product is important. It allows continued monitoring of the benefit/risk balance of the medical product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting listed in Appendix V*.
[*For the printed material, please refer to the guidance of the annotated QRD template.]
4.9 Overdose
No case of overdose has been reported.
5 Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antihemorrhagics: blood coagulation factor VIII
ATC-Code: B02BD02
The factor VIII/ von Willebrand factor complex consists of two molecules (FVIII and vWF) with different physiological functions. When infused into a haemophiliac patient, factor VIII binds to von Willebrand factor in the patient’s circulation.
Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed.
Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C and results in profuse bleeding into joints, muscles, or internal organs, either spontaneously or as a results of accidental or surgical trauma. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.
Octanate is being assessed for induction of immune tolerance induction (ITI) therapy in an ongoing observational clinical study.
In an interim analysis of the 69 patients so far treated with Octanate via ITI, 49 patients have completed the study. In the patients where the inhibitor was successfully eliminated, the monthly bleeding rates were significantly reduced.
5.2 Pharmacokinetic properties
Human
plasma coagulation factor VIII (from the powder) is a normal
constituent of the human plasma and acts like the endogenous factor
VIII. After injection of the product, approximately two-thirds to
three-quarter of the factor VIII remain in the circulation. The
level of factor VIII activity reached in the plasma should be
between 80% - 120% of the predicted factor VIII activity.
Plasma factor VIII activity decreases by a two-phase exponential
decay. In the initial phase, distribution between the intravascular
and other compartments (body fluids) occurs with a half-life of
elimination from the plasma of 3 to 6 hours. In the subsequent
slower phase (which probably reflects the consumption of factor
VIII), the half-life varies between 8 to 20 hours, with an average
of 12 hours. This corresponds to the true biological
half-life.
For Octanate the following results were achieved for two pharmacokinetic studies with 10 and 14 haemophilia A patients, respectively:
|
|
Recovery |
AUC*norm |
Half-life |
MRT* |
Clearance |
|
Study 1, n = 10 Mean ± SD* |
2.4 ± 0.36 |
45.5 ± 17.2 |
14.3 ± 4.01 |
19.6 ± 6.05 |
2.6 ± 1.21 |
|
Study 2, n = 14 Mean ± SD* |
2.4 ± 0.25 |
33.4 ± 8.50 |
12.6 ± 3.03 |
16.6 ± 3.73 |
3.2 ± 0.88 |
AUC* = area under the curve,
MRT* = mean residence time,
SD* = standard deviation
5.3 Preclinical safety data
Toxicological data available on tri-n-butylphosphate (TNBP) and polysorbate 80 (tween 80), the solvent/detergent reagents used in the SD method of viral inactivation during manufacture of Octanate, although limited for the latter, indicate that adverse effects are unlikely at the anticipated human exposures.
Even doses of several times the recommended human dosage per kilogram body weight of these reagents show no toxic effects on laboratory animals. No mutagenic potential was observed for either of the two substances.
6 Pharmaceutical Particulars
6.1 List of excipients
Powder:
-
Sodium citrate
-
Sodium chloride
-
Calcium chloride
-
Glycine
Solvent: Water for injections
6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Only the provided injection or infusion sets should be used, because treatment failure can occur as a consequence of human coagulation factor VIII adsorption to the internal surface of some injection/infusion equipment.
6.3 Shelf life
2 years
The reconstituted solution must be used immediately and for single use only.
6.4 Special precautions for storage
Store in a refrigerator (2°C - 8°C).
Do not freeze.
Keep the vials in the outer carton in order to protect from light.
For storage conditions after reconstitution of the medicinal product, see section 6.3.
6.5 Nature and contents of container
One package Octanate contains:
-
Powder in a vial (type I glass), with a stopper (chlorobutyl or bromobutyl rubber), and a flip off cap
-
solvent in a vial (type I glass), with a stopper (chlorobutyl or bromobutyl rubber), and a flip off cap
-
one disposable syringe, one transfer set Mix2VialTM, one injection set, and two alcohol swabs.
One vial of Octanate contains 1000 IU of human coagulation factor VIII.
6.6 Special precautions for disposal and other handling
-
Please read all the instructions and follow them carefully!
-
Do not use Octanate after expiry date given on the label.
-
During the procedure described below, sterility must be maintained!
-
The solution should be clear or slightly opalescent. Do not use solutions that are cloudy or have deposits.
-
Use the prepared solution immediately, to prevent microbial contamination.
-
Only use the injection set provided. The use of other injection/infusion equipment can cause additional risks and treatment failure.
Instructions for preparing the solution:
1. Do not use the product directly from the refrigerator. Allow the solvent and the powder in the closed vials to reach room temperature.
2. Remove the flip off caps from both vials and clean the rubber stoppers with one of the provided alcohol swabs.
3. The Mix2vial™ is depicted in Fig. 1. Place the solvent vial on an even surface and hold it firmly. Take the Mix2Vial™ and turn it upside down. Place the blue part of the Mix2Vial™ on top of the solvent vial and press firmly down until it snaps (Fig. 2+3).
